TrivarX Limited (AU:TRI) has released an update.
TrivarX Limited has reported promising results from its Phase 2 SAMDE study, showing its AI-driven algorithm, MEB-001, has the potential to significantly improve depression screening. With an 87% sensitivity rate, these findings bolster TrivarX’s ongoing efforts to engage with the FDA for a pivotal trial, a crucial step towards obtaining regulatory approval. The company also enhanced its leadership team with new appointments to support its strategic objectives.
For further insights into AU:TRI stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
